View ValuationThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsBenevolentAI 将来の成長Future 基準チェック /36BenevolentAI利益と収益がそれぞれ年間72.4%と26.8%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に20.9% 76.3%なると予測されています。主要情報72.4%収益成長率76.30%EPS成長率Pharmaceuticals 収益成長14.4%収益成長率26.8%将来の株主資本利益率20.87%アナリストカバレッジLow最終更新日14 Mar 2025今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Mar 14BenevolentAI Announces Delisting from Euronext Amsterdam Effective 13 March 2025BenevolentAI S.A. announced that their shares will be delisted from Euronext Amsterdam effective 13 March 2025.お知らせ • Feb 08BenevolentAI S.A. Proposes Delisting from Euronext Amsterdam N.VFollowing the announcement on 11 December 2024 and subsequent further detailed review and evaluation, the Board of BenevolentAI S.A. has concluded that delisting from Euronext Amsterdam N.V. (“Euronext”) and transitioning to a private company is in the best interests of the Company and its shareholders. The Board determined that the financial and administrative costs of maintaining a public listing are not justified by the benefits. By eliminating the significant costs associated with its public status, including legal, regulatory, financial, and administrative overheads, the Company can redeploy this capital towards core business activities that drive innovation and product development. This aims to deliver greater value to its shareholders, partners and ultimately benefit the patients it serves. The proposed Delisting and Merger of BenevolentAI into Osaka Holdings requires passing EGM Resolutions (as defined and set out below). It is important for shareholders to understand that should any of the Resolutions fail to pass, the Delisting and Merger will not proceed. Delisting will be implemented via a merger of BenevolentAI into Osaka Holdings. Osaka Holdings is currently a private limited liability company (société à responsabilité limitée) incorporated under the laws of the Grand Duchy of Luxembourg with its registered office at 9, rue de Bitbourg, L-1273 Luxembourg. It is not listed on any exchange and has no assets and no liabilities other than its share capital which will be reduced to zero on Merger. Upon the Merger, scheduled for completion on 12 March 2025, all the Company’s assets, liabilities, rights and obligations will transfers to Osaka Holdings under universal title of succession. If the Resolutions are passed at the EGM, the Merger will become effective once both BenevolentAI and Osaka Holdings have adopted the concurring approval decisions during their respective general meetings on the same day. Consequently, it is envisaged that the Delisting will become effective on 13 March 2025. Upon Delisting, the last day of trading in the class A shares and class A warrants will be 12 March 2025. The EGM will be held on 12 March 2025.お知らせ • Oct 17+ 1 more updateBenevolentAI S.A. Appoints Michael Brennan as Chief Financial OfficerBenevolentAI announced the appointment of Michael Brennan as Chief Financial Officer, further strengthening the Company’s leadership. A co-founder of BenevolentAI, Michael brings a wealth of expertise from senior roles across the biotechnology, technology and investment banking sectors. His appointment reflects the Company’s focus on strengthening its commercial and financial position and driving future growth.お知らせ • Sep 17BenevolentAI S.A. to Report First Half, 2024 Results on Sep 19, 2024BenevolentAI S.A. announced that they will report first half, 2024 results on Sep 19, 2024お知らせ • Jul 04BenevolentAI S.A. Announces CFO ChangesBenevolentAI S.A. announced a change to its Executive Leadership Team (ELT) following the recent Annual General Meeting and the election of a new Board of Directors. In a move to better enhance operational efficiency and strategic focus, the Board initiated a leadership review to better support BenevolentAI's ambitious growth plans. The results of the review include Ms. Catherine Isted stepping down from her role as Chief Financial Officer. Mr. Tom Holgate, who has been at BenevolentAI for nearly seven years, will continue in his role as Group Finance Director, ensuring continuity and leveraging his extensive understanding of the Company's financial landscape to lead several pivotal financial initiatives. The company is intensifying its efforts to capitalise on the expanding opportunities within the rapidly maturing 'techbio' sector. BenevolentAI's strong momentum is underscored by last week’s successful integration of a novel target in Systemic Lupus Erythematosus into AstraZeneca's portfolio, marking yet another significant milestone for the Company and the second major collaboration milestone achieved with AstraZeneca this year. The Board's review further highlighted the need to adopt a more dynamic and entrepreneurial approach across the Company’s leadership, business development activities, and internal management structures. These changes are designed to expand the Company's market share in the AI-driven drug discovery sector, accelerate the development of its internal pipelines, and forge new strategic collaborations.お知らせ • May 03Benevolentai S.A. Announces Directorate ChangesBenevolentAI announced that all resolutions proposed at its Annual General Meeting were duly passed. In line with the AGM resolutions, Mr. Peter Allen, Mr. Kenneth Mulvany, Mr. Ian Nicholson and Mr. Jeremy Sohn, have joined the Board of the Company as Non-Executive Directors. As per the Company’s announcement of 15 April 2024, the close of the AGM has also resulted in the resignations of Dr François Nader, Dr Olivier Brandicourt, Dr Susan Liautaud and Mr. Marcello Damiani, as Non-Executive Directors of BenevolentAI, becoming effective. The Board now consists of eight persons, seven Non-Executive Directors and Dr Joerg Moeller, CEO and Executive Director of the Company. The position of the Chair of the Board and the composition of Board Committees will be determined at the time of the first board meeting and will be communicated thereafter.お知らせ • Apr 15BenevolentAI S.A. Announces Board Resignations, Effective from May 2, 2024BenevolentAI S.A. announced that Dr. François Nader, Chair of the Board, Dr. Olivier Brandicourt, Dr. Susan Liautaud and Mr. Marcello Damiani, all Non-Executive Directors, will resign as directors of BenevolentAI effective as of the close of the Company’s AGM on 2 May 2024.お知らせ • Apr 03Kenneth Mulvany Sends a Letter to Benovelent AIOn April 2, 2024, Kenneth Mulvany stated that he has sent a letter to Benovelent AI, stating that he has raised concerns about the Company's cost management, business development resourcing, strategy, investor relations and governance. In addition, Kenneth Mulvany stated that in his letter he declared his intention to nominate a slate of director candidates that aim to strengthen governance and accountability, invigorate the Company's business development, sharpen its strategic focus, offer clear market communication, and rebuild confidence among our investors and stakeholders, and this declaration paves the way for him to seek the support of shareholders at the forthcoming Annual General Meeting, for Board reform. Further, Kenneth Mulvany stated that he will be focusing the Board's efforts to prioritize stringent cost management and revenue growth, along with expanding strategic partnerships and with the support of shareholders, he prepared to take on a director role.お知らせ • Mar 20+ 1 more updateBenevolentAI S.A., Annual General Meeting, May 02, 2024BenevolentAI S.A., Annual General Meeting, May 02, 2024, at 14:00 Central European Standard Time. Location: 2, place Winston Churchill, L-1340 Luxembourgお知らせ • Mar 04BenevolentAI S.A. to Report Fiscal Year 2023 Results on Mar 14, 2024BenevolentAI S.A. announced that they will report fiscal year 2023 results on Mar 14, 2024お知らせ • Jan 24BenevolentAI Appoints Joerg Moeller as Chief Executive OfficerBenevolentAI announced the appointment of Dr. Joerg Moeller as Chief Executive Officer and Executive Board member with immediate effect. Dr. Joerg Moeller, MD, PhD, brings a wealth of experience to BenevolentAI. During his career, he has led global research and development (R&D) organisations, successfully demonstrating innovation, commercial and operational excellence which resulted in long-term productivity and value creation. He initiated several drug discovery collaborations with artificial Intelligence (AI) platform companies and is a strong advocate of this strategy of accessing innovation. Throughout his career, Dr. Moeller has also forged strategic business development transactions through out-licensing assets as well as partnerships and is a well-known and respected figure within the target stakeholders of BenevolentAI. Most recently, Dr. Moeller served as EVP, Head of Global Research and Development and Member of the Global Leadership Team of LEO Pharma A/S (LEO). During his tenure, he re-organised and re-structured the global R&D organisation to support growth and innovation ambitions of the company. Prior to LEO Pharma Dr. Moeller was at Bayer AG (Bayer) for over 20 years where he held various executive roles culminating in his appointment as EVP, Head of Pharmaceuticals Research and Development and Member of the Executive Committee of the Pharmaceuticals Division of Bayer. He successfully managed development and global product approvals, redefined Bayer’s pipeline strategy and brought on external strategic AI collaborations. Dr. Moeller currently serves on the Board of Secura Bio, a privately-held US biotech company. He graduated as a Doctor of Medicine and holds a PhD from Ruhr University Bochum, Germany. Dr. Moeller will be based in the London headquarters of BenevolentAI. Dr. François Nader will now revert to his previous position of Independent Non-Executive Chair and will work closely with him to ensure a smooth onboarding.業績と収益の成長予測OTCPK:BAIV.F - アナリストの将来予測と過去の財務データ ( )GBP Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2027N/AN/AN/AN/A112/31/202665303335112/31/202515-41-39-35212/31/20248-55-49-5026/30/20245-51-48-47N/A3/31/20246-57-53-52N/A12/31/20237-63-58-57N/A9/30/20239-61-70-69N/A6/30/202311-59-82-80N/A3/31/202311-112-80-79N/A12/31/202211-164-78-77N/A9/30/20229-186-76-74N/A6/30/20228-208-73-72N/A3/31/20226-158-61-60N/A12/31/20215-108-50-49N/A12/31/20207-55-36-35N/A12/31/20195-48-30-29N/A12/31/20187-27-42-38N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: BAIV.F今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: BAIV.F今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: BAIV.F今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: BAIV.Fの収益 ( 26.8% ) US市場 ( 11.7% ) よりも速いペースで成長すると予測されています。高い収益成長: BAIV.Fの収益 ( 26.8% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: BAIV.Fの 自己資本利益率 は、3年後には高くなると予測されています ( 20.9 %)成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/03/14 21:22終値2025/02/14 00:00収益2024/06/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋BenevolentAI S.A. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Rajan SharmaGoldman SachsRichard VosserJ.P. MorganJames GordonJ.P. Morgan1 その他のアナリストを表示
お知らせ • Mar 14BenevolentAI Announces Delisting from Euronext Amsterdam Effective 13 March 2025BenevolentAI S.A. announced that their shares will be delisted from Euronext Amsterdam effective 13 March 2025.
お知らせ • Feb 08BenevolentAI S.A. Proposes Delisting from Euronext Amsterdam N.VFollowing the announcement on 11 December 2024 and subsequent further detailed review and evaluation, the Board of BenevolentAI S.A. has concluded that delisting from Euronext Amsterdam N.V. (“Euronext”) and transitioning to a private company is in the best interests of the Company and its shareholders. The Board determined that the financial and administrative costs of maintaining a public listing are not justified by the benefits. By eliminating the significant costs associated with its public status, including legal, regulatory, financial, and administrative overheads, the Company can redeploy this capital towards core business activities that drive innovation and product development. This aims to deliver greater value to its shareholders, partners and ultimately benefit the patients it serves. The proposed Delisting and Merger of BenevolentAI into Osaka Holdings requires passing EGM Resolutions (as defined and set out below). It is important for shareholders to understand that should any of the Resolutions fail to pass, the Delisting and Merger will not proceed. Delisting will be implemented via a merger of BenevolentAI into Osaka Holdings. Osaka Holdings is currently a private limited liability company (société à responsabilité limitée) incorporated under the laws of the Grand Duchy of Luxembourg with its registered office at 9, rue de Bitbourg, L-1273 Luxembourg. It is not listed on any exchange and has no assets and no liabilities other than its share capital which will be reduced to zero on Merger. Upon the Merger, scheduled for completion on 12 March 2025, all the Company’s assets, liabilities, rights and obligations will transfers to Osaka Holdings under universal title of succession. If the Resolutions are passed at the EGM, the Merger will become effective once both BenevolentAI and Osaka Holdings have adopted the concurring approval decisions during their respective general meetings on the same day. Consequently, it is envisaged that the Delisting will become effective on 13 March 2025. Upon Delisting, the last day of trading in the class A shares and class A warrants will be 12 March 2025. The EGM will be held on 12 March 2025.
お知らせ • Oct 17+ 1 more updateBenevolentAI S.A. Appoints Michael Brennan as Chief Financial OfficerBenevolentAI announced the appointment of Michael Brennan as Chief Financial Officer, further strengthening the Company’s leadership. A co-founder of BenevolentAI, Michael brings a wealth of expertise from senior roles across the biotechnology, technology and investment banking sectors. His appointment reflects the Company’s focus on strengthening its commercial and financial position and driving future growth.
お知らせ • Sep 17BenevolentAI S.A. to Report First Half, 2024 Results on Sep 19, 2024BenevolentAI S.A. announced that they will report first half, 2024 results on Sep 19, 2024
お知らせ • Jul 04BenevolentAI S.A. Announces CFO ChangesBenevolentAI S.A. announced a change to its Executive Leadership Team (ELT) following the recent Annual General Meeting and the election of a new Board of Directors. In a move to better enhance operational efficiency and strategic focus, the Board initiated a leadership review to better support BenevolentAI's ambitious growth plans. The results of the review include Ms. Catherine Isted stepping down from her role as Chief Financial Officer. Mr. Tom Holgate, who has been at BenevolentAI for nearly seven years, will continue in his role as Group Finance Director, ensuring continuity and leveraging his extensive understanding of the Company's financial landscape to lead several pivotal financial initiatives. The company is intensifying its efforts to capitalise on the expanding opportunities within the rapidly maturing 'techbio' sector. BenevolentAI's strong momentum is underscored by last week’s successful integration of a novel target in Systemic Lupus Erythematosus into AstraZeneca's portfolio, marking yet another significant milestone for the Company and the second major collaboration milestone achieved with AstraZeneca this year. The Board's review further highlighted the need to adopt a more dynamic and entrepreneurial approach across the Company’s leadership, business development activities, and internal management structures. These changes are designed to expand the Company's market share in the AI-driven drug discovery sector, accelerate the development of its internal pipelines, and forge new strategic collaborations.
お知らせ • May 03Benevolentai S.A. Announces Directorate ChangesBenevolentAI announced that all resolutions proposed at its Annual General Meeting were duly passed. In line with the AGM resolutions, Mr. Peter Allen, Mr. Kenneth Mulvany, Mr. Ian Nicholson and Mr. Jeremy Sohn, have joined the Board of the Company as Non-Executive Directors. As per the Company’s announcement of 15 April 2024, the close of the AGM has also resulted in the resignations of Dr François Nader, Dr Olivier Brandicourt, Dr Susan Liautaud and Mr. Marcello Damiani, as Non-Executive Directors of BenevolentAI, becoming effective. The Board now consists of eight persons, seven Non-Executive Directors and Dr Joerg Moeller, CEO and Executive Director of the Company. The position of the Chair of the Board and the composition of Board Committees will be determined at the time of the first board meeting and will be communicated thereafter.
お知らせ • Apr 15BenevolentAI S.A. Announces Board Resignations, Effective from May 2, 2024BenevolentAI S.A. announced that Dr. François Nader, Chair of the Board, Dr. Olivier Brandicourt, Dr. Susan Liautaud and Mr. Marcello Damiani, all Non-Executive Directors, will resign as directors of BenevolentAI effective as of the close of the Company’s AGM on 2 May 2024.
お知らせ • Apr 03Kenneth Mulvany Sends a Letter to Benovelent AIOn April 2, 2024, Kenneth Mulvany stated that he has sent a letter to Benovelent AI, stating that he has raised concerns about the Company's cost management, business development resourcing, strategy, investor relations and governance. In addition, Kenneth Mulvany stated that in his letter he declared his intention to nominate a slate of director candidates that aim to strengthen governance and accountability, invigorate the Company's business development, sharpen its strategic focus, offer clear market communication, and rebuild confidence among our investors and stakeholders, and this declaration paves the way for him to seek the support of shareholders at the forthcoming Annual General Meeting, for Board reform. Further, Kenneth Mulvany stated that he will be focusing the Board's efforts to prioritize stringent cost management and revenue growth, along with expanding strategic partnerships and with the support of shareholders, he prepared to take on a director role.
お知らせ • Mar 20+ 1 more updateBenevolentAI S.A., Annual General Meeting, May 02, 2024BenevolentAI S.A., Annual General Meeting, May 02, 2024, at 14:00 Central European Standard Time. Location: 2, place Winston Churchill, L-1340 Luxembourg
お知らせ • Mar 04BenevolentAI S.A. to Report Fiscal Year 2023 Results on Mar 14, 2024BenevolentAI S.A. announced that they will report fiscal year 2023 results on Mar 14, 2024
お知らせ • Jan 24BenevolentAI Appoints Joerg Moeller as Chief Executive OfficerBenevolentAI announced the appointment of Dr. Joerg Moeller as Chief Executive Officer and Executive Board member with immediate effect. Dr. Joerg Moeller, MD, PhD, brings a wealth of experience to BenevolentAI. During his career, he has led global research and development (R&D) organisations, successfully demonstrating innovation, commercial and operational excellence which resulted in long-term productivity and value creation. He initiated several drug discovery collaborations with artificial Intelligence (AI) platform companies and is a strong advocate of this strategy of accessing innovation. Throughout his career, Dr. Moeller has also forged strategic business development transactions through out-licensing assets as well as partnerships and is a well-known and respected figure within the target stakeholders of BenevolentAI. Most recently, Dr. Moeller served as EVP, Head of Global Research and Development and Member of the Global Leadership Team of LEO Pharma A/S (LEO). During his tenure, he re-organised and re-structured the global R&D organisation to support growth and innovation ambitions of the company. Prior to LEO Pharma Dr. Moeller was at Bayer AG (Bayer) for over 20 years where he held various executive roles culminating in his appointment as EVP, Head of Pharmaceuticals Research and Development and Member of the Executive Committee of the Pharmaceuticals Division of Bayer. He successfully managed development and global product approvals, redefined Bayer’s pipeline strategy and brought on external strategic AI collaborations. Dr. Moeller currently serves on the Board of Secura Bio, a privately-held US biotech company. He graduated as a Doctor of Medicine and holds a PhD from Ruhr University Bochum, Germany. Dr. Moeller will be based in the London headquarters of BenevolentAI. Dr. François Nader will now revert to his previous position of Independent Non-Executive Chair and will work closely with him to ensure a smooth onboarding.